Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H21F2N5O2S |
| Molecular Weight | 505.539 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(C=N1)C2=CC3=C(C=C2)N(C=N3)C4=CC(NS(=O)(=O)C5CC5)=CC(=C4)C6=CC=C(F)C=C6F
InChI
InChIKey=ZJFCBQXPTQSTCZ-UHFFFAOYSA-N
InChI=1S/C26H21F2N5O2S/c1-32-14-18(13-30-32)16-2-7-26-25(10-16)29-15-33(26)21-9-17(23-6-3-19(27)11-24(23)28)8-20(12-21)31-36(34,35)22-4-5-22/h2-3,6-15,22,31H,4-5H2,1H3
| Molecular Formula | C26H21F2N5O2S |
| Molecular Weight | 505.539 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1539 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FED |
|
2608 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1933 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3118 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FED |
|
4906 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
9070 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25886 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FED |
|
36708 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
30257 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
58612 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FED |
|
84233 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
170304 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33262202/ |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ODM-203 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 13:43:16 GMT 2025
by
admin
on
Wed Apr 02 13:43:16 GMT 2025
|
| Record UNII |
Y7HJ4D4CRT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1430723-35-5
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
PRIMARY | |||
|
300000042523
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
PRIMARY | |||
|
71554322
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
PRIMARY | |||
|
Y7HJ4D4CRT
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
PRIMARY | |||
|
C118628
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
PRIMARY | |||
|
1814961-19-7
Created by
admin on Wed Apr 02 13:43:16 GMT 2025 , Edited by admin on Wed Apr 02 13:43:16 GMT 2025
|
NO STRUCTURE GIVEN |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
